<?xml-stylesheet type="text/xsl" href="journal_ViewIMF-v1.0.xsl"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Iran. J. Public Health</journal-id><journal-id journal-id-type="publisher-id">IJPH</journal-id><journal-title-group><journal-title>Iranian Journal of Public Health</journal-title></journal-title-group><issn pub-type="ppub">2251-6085</issn><issn pub-type="epub">2251-6093</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26060625</article-id><article-id pub-id-type="pmc">4436545</article-id><article-id pub-id-type="art-access-id">IJPH-42-1158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Randomized, Controlled Trial of Levonorgestrel Vs. The Yuzpe Regimen as Emergency Contraception Method among Iranian Women</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hoseini</surname><given-names>Fatemeh Sadat</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eslami</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Abbasi</surname><given-names>Mohammed</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Noroozi Fashkhami</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Besharati</surname><given-names>Soheila</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1">1. <institution>Dept. of Anatomy, School of Medicine, Tehran University of Medical Sciences</institution>, <country>Tehran, Iran</country></aff><aff id="aff2">2. <institution>Dept. of Population, Family and School Health, Ministry of Health and Medical Education</institution>, <country>Tehran, Iran</country></aff><aff id="aff3">3. <institution>Family Planning Office, Gilan University of Medical Sciences</institution>, <country>Rasht, Iran</country></aff><author-notes><corresp id="fn001">* <bold>Corresponding Author:</bold> Email: <email xlink:type="simple">fshoseini@razi.tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2013</year></pub-date><volume>42</volume><issue>10</issue><fpage>1158</fpage><lpage>1166</lpage><history><date date-type="received"><day>20</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Iranian Public Health Association &#x00026; Tehran University of Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Background</title><p>We aimed to compare acceptability of Levonorgestrel with the Yuzpe regimen among Iranian women based on their side-effects and resulting changes in the amount and pattern of menses.</p></sec><sec><title>Methods</title><p>Five hundred twenty nine participants aged 15-49 having regular menses and one act of unprotected intercourse within 72 h were included in the double-blind, controlled trial in 2006-2007 and randomly assigned into LNG (n=263) and HD (n=266) groups, receiving Levonorgestrel 0.75 mg given 12 h apart and ethinyl estradiol 100 &#x003bc;g plus 0.5 mg Levonorgestrel 0.5 mg repeated after 12 h, respectively.</p></sec><sec><title>Results</title><p>The participants receiving Levonorgestrel experienced significantly lower side-effects in the case of nausea, vomiting, and dizziness (<italic>P</italic>&#x0003c;0.05). The changes occurred in the amount and pattern of menses were the same for both groups (<italic>P</italic>&#x0003e;0.05). No significant difference was observed between the efficiencies of the treatments.</p></sec><sec><title>Conclusion</title><p>Significantly lower side-effects of Levonorgestrel can be considered as greater acceptability and translated to higher efficiency.</p></sec></abstract><kwd-group><kwd>Levonorgestrel</kwd><kwd>Yuzpe regimen</kwd><kwd>Emergency contraception</kwd><kwd>Side-effects</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Seventy five million unwanted pregnancies annually occur in the world, 50 million of which lead to termination of pregnancy and 20 million ends up with unsafe abortions. Itresults to 55000 deaths happen in the world, particularly in developing countries (95%) (<xref rid="ref1" ref-type="bibr">1</xref>). The number of unwanted pregnancies in Iran, as a developing country, is about 500000 annually, 16% of which leads to termination of pregnancy (<xref rid="ref2" ref-type="bibr">2</xref>). The main reasons for unwanted pregnancies are failure of contraceptive methods such as condom breakage or slippage and miscalculation of infertile period, or in some situations forced sex and unmet need (<xref rid="ref3" ref-type="bibr">3</xref>). This can, however, be easily prevented by using emergency contraceptive pills (ECPs) or so-called &#x0201c;morning-after pills&#x0201d; that are considered to be effective if taken within 5 days of unguarded intercourse (<xref rid="ref4" ref-type="bibr">4</xref>), though it was priory believed that they have to be taken within 72 h. This method can highly decrease the costs posed to health care providers due to unwanted pregnancies (<xref rid="ref5" ref-type="bibr">5</xref>&#x02013;<xref rid="ref7" ref-type="bibr">7</xref>).</p><p>The first emergency contraceptive method was introduced by Yuzpe(<xref rid="ref8" ref-type="bibr">8</xref>) which is called &#x0201c;Yuzpe regimen&#x0201d;. Afterwards, the efficacy of the method was evaluated by several studies and it was found that the Yuzpe regimen is quite an effective method of emergency contraception (<xref rid="ref9" ref-type="bibr">9</xref>), but it has some side effects such as vomiting, nausea, dizziness, and fatigue (<xref rid="ref10" ref-type="bibr">10</xref>). Mifepristone and Danazol have also been introduced as alternative methods of emergency contraception and assessed by various studies. Danazol was found to be an inefficient method of contraception (<xref rid="ref11" ref-type="bibr">11</xref>). Mifepristone, however, is an effective method of contraception (<xref rid="ref12" ref-type="bibr">12</xref>), have milder side effects than Yuzpe(<xref rid="ref13" ref-type="bibr">13</xref>), but because it affects menstrual cycle (<xref rid="ref11" ref-type="bibr">11</xref>) and is associated with induced abortion (<xref rid="ref10" ref-type="bibr">10</xref>), it is not widely used. Because of disadvantages of all aforementioned contraceptive methods, a new regimen, called &#x0201c;Levonorgestrel only&#x0201d;, was proposed (<xref rid="ref14" ref-type="bibr">14</xref>) and its efficacy and side effects have been highly evaluated. The most comprehensive, multicenter, randomized controlled trial on the efficacy of Levonorgestrel only showed that efficacy of this method is higher than that of Yuzpe regimen by a factor of 3 and has considerably fewer side effects (<xref rid="ref15" ref-type="bibr">15</xref>). The findings were supported by another RCT (<xref rid="ref16" ref-type="bibr">16</xref>). There are two regimens of Levonorgestrel: A double o.75 mg dose of Levonorgestrel taken 12 h apart; and a single 1.5 mg dose. Both mentioned regimens have the same effectiveness (<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>), so with the advent of the single-dose method, use of hormonal contraceptives can be highly simplified, particularly if taken in the afternoon (<xref rid="ref19" ref-type="bibr">19</xref>). Other aspects of ECP<sub>s</sub> are well described and discussed in the literature (<xref rid="ref20" ref-type="bibr">20</xref>&#x02013;<xref rid="ref22" ref-type="bibr">22</xref>).</p><p>The only problem that remains unsolved is the change occurs in normal time and length of menstrual bleeding due to use of ECP<sub>s</sub>(<xref rid="ref3" ref-type="bibr">3</xref>), particularly in the case of Levonorgestrel (<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>). On the other hand, the time and length of spotting is quite important for Iranian women because every change in the time and length of menses affects their religious activities and interferes with them. In addition, few studies have been conducted in Iran exploring the efficacy of Yuzpe regimen compared to Levono-rgestrel (<xref rid="ref25" ref-type="bibr">25</xref>, <xref rid="ref26" ref-type="bibr">26</xref>). However, these studies were conducted using very small sample sizes and did not measure the serum levels of Beta-HCG before administrating the pills.</p><p>The present study, therefore, aimed at evaluating the pattern of menstrual bleeding in the two efficient methods of emergency contraception, namely, Levonorgestrel only and Yuzpe regimens among woman in Gilan province, Iran, who had had unguarded intercourse and seeked post coital contraception. We also assessed the efficacy, side effects, and acceptability of aforementioned method in participants. Results of this study can be used for future policy making on the best and the most acceptable method of emergency contraception according to cultural and religious beliefs in Iran.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Protocol</title><p>Eligible participants were sexually active women aged between 15 and 49 years having regular menstrual cycles of 24-42 days. We also included women having only one act of unprotected intercourse within current cycle and they were asked to take the pills within 72 h of the unprotected intercourse. In addition, the failed contraceptive method was determined to be condom or conventional method. Breast-feeding women were also included provided that their baby was older than 6 months. Exclusion criteria were breast-feeding women with their baby younger than 6 months, hormonal contraindications in their current cycle, use of hormonal contraceptives, uncertainty about the time of LMP, and suspected pregnancy.</p><p>Between 12 Sep 2006 and 25 Jun 2007 after complying with inclusion criteriaparticipants were asked to sign the written consent. Participants were then classified into two groups (i.e. HD regimen and LNG regimen groups) according to balanced black randomization. Four tablets in the same size, shape, and color were put in each set. Neither the obstetrics, nor the participants were aware of the type of tablets in each set (double-blind). Only the person responsible for randomization was aware of the contents of the sets according to the serial numbers stuck on the sets. Levonorgestrel regimen (LNG group) consisted of two sets; each one contained a 0.75 mg Levonorgestrel and a placebo tablet; the pills in each set were taken at once and the sets were taken 12 h apart. Yuzpe regimen (HD group) consisted of four white tablets; two HD pills were put in a set. The pills in each set were taken at once and the sets were taken 12 h apart. The third dose (two pills) was also given to the participants to be taken if regurgitating within two hours of drug administration. The first set of tablets was taken in presence of the obstetrics and the second set was taken at home 12 h later. The article was registered formally as the following code: IRCT ID: IRCT2013091112307N2.</p></sec><sec><title>Data collection and follow-up</title><p>The first form that was filled out by the midwife at the first day consisted of questions on demographic characteristics and medical status of the participant-ants. Their weight and height were also measured to calculate BMI. On the second form, participants were asked to write down the time of administration of the second dose and any possible side effects experienced. Third form was filled out by the midwife one week after expected menses and contained information regarding possible changes occurred in normal pattern of menstrual bleeding. Side effects were only assessed among participants who had met drug administration criteria.</p></sec><sec><title>Sample size calculations</title><p>According to the most comprehensive study on the efficacies of Levonorgestrel and Yuzpe regimens (<xref rid="ref15" ref-type="bibr">15</xref>), only 2.1% difference exists between pregnancy rates of above mentioned methods. Hence, power calculations revealed that 744 participants in each treatment group would have needed if the same difference had expected to be observed in our society.</p></sec><sec><title>Data analysis</title><p>Having handled the outlier data, descriptive analyses was conducted using SPSS software. Group-specified descriptive analyzes were then performed for both treatment groups. Afterwards, comparisons were made between the two groups employing chi-square and <italic>t</italic>-test. Outcome measures were then compared between treatment groups. Having done the analyses, data were decoded and the results were assigned to each group.</p></sec></sec><sec><title>Results</title><p>Five hundred twenty nine women met eligibility criteria and participated in this study (two hundred sixty six women in HD group and two hundred sixty three women in LNG group), among which four hundred forty eight women lived in Rasht and eighty one women lived in Bandar Anzali, northern of Iran. No statistically significant differences were observed in job, level of education, living area, and previously used contraceptive method between treatment groups.</p><p><xref ref-type="table" rid="T1">Table 1</xref> shows baseline characteristics of eligible participants. Because of effective randomization, no statistically significant differences were observed in baseline characteristics of the two groups. Majority of the participants were in their late 20s (average 28.8 years old) and almost half of each group had previously used condom as the method of contraception. The participants in both groups were also equal in the knowledge of emergency contraception (<xref ref-type="table" rid="T2">Table 2</xref>) and one third in each group had experienced use of emergency contraceptive pills.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1:</label><caption><p>Baseline characteristics of eligible participants</p></caption><table frame="hsides" rules="all" cellspacing="5" cellpadding="5" border="1"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Mean (SD) in HD group</th><th valign="top" align="center" rowspan="1" colspan="1">Mean (SD) in LNG group</th><th valign="top" align="center" rowspan="1" colspan="1">Mean (SD) total</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value <break/>(chi-square)</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="2" rowspan="1">Age</td><td valign="top" align="center" rowspan="1" colspan="1">28.8 (6.2)</td><td valign="top" align="center" rowspan="1" colspan="1">28.8 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">28.8 (5.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.874</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Weight</td><td valign="top" align="center" rowspan="1" colspan="1">66.7 (12.1)</td><td valign="top" align="center" rowspan="1" colspan="1">67.4 (11.4)</td><td valign="top" align="center" rowspan="1" colspan="1">67.0 (11.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.493</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Height</td><td valign="top" align="center" rowspan="1" colspan="1">159.4 (5.8)</td><td valign="top" align="center" rowspan="1" colspan="1">160.0 (5.5)</td><td valign="top" align="center" rowspan="1" colspan="1">159.6 (5.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.257</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">BMI</td><td valign="top" align="center" rowspan="1" colspan="1">26.3 (4.6)</td><td valign="top" align="center" rowspan="1" colspan="1">26.3 (4.2)</td><td valign="top" align="center" rowspan="1" colspan="1">26.3 (4.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.893</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Number of pregnancies</td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (1.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.7 (1.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.8 (1.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.484</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Number of childbirth</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (0.7)</td><td valign="top" align="center" rowspan="1" colspan="1">1.4 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.862</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Number of abortions</td><td valign="top" align="center" rowspan="1" colspan="1">0.3 (0.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.3 (0.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.3 (0.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.252</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frequency (percentage) of prior contraceptive method</td><td valign="top" align="center" rowspan="1" colspan="1">Condom</td><td valign="top" align="center" rowspan="1" colspan="1">142 (54%)</td><td valign="top" align="center" rowspan="1" colspan="1">167 (48.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">269 (51.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.239</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Conventional</td><td valign="top" align="center" rowspan="1" colspan="1">121 (46%)</td><td valign="top" align="center" rowspan="1" colspan="1">133 (51.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">254 (48.6%)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2:</label><caption><p>Knowledge and prior experience of emergency contraception among participants in both treatment groups</p></caption><table frame="hsides" rules="all" cellspacing="5" cellpadding="5" border="1"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">Status</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) in HD group</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) in LNG group</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) total</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value <break/>(chi-square)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Knowledge of ECPs</td><td valign="top" align="center" rowspan="1" colspan="1">Perfect knowledge</td><td valign="top" align="center" rowspan="1" colspan="1">21 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (8.3)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Know HD and LD pills</td><td valign="top" align="center" rowspan="1" colspan="1">122 (46.4)</td><td valign="top" align="center" rowspan="1" colspan="1">118 (46.3)</td><td valign="top" align="center" rowspan="1" colspan="1">240 (46.3)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Do not know number of pills</td><td valign="top" align="center" rowspan="1" colspan="1">4 (1.5)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (2)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (1.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Know the access method</td><td valign="top" align="center" rowspan="1" colspan="1">48 (18.3)</td><td valign="top" align="center" rowspan="1" colspan="1">60 (23.5)</td><td valign="top" align="center" rowspan="1" colspan="1">108 (20.8)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Do not know ECPs</td><td valign="top" align="center" rowspan="1" colspan="1">68 (25.9)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">118 (22.8)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Prior use of</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">89 (33.6)</td><td valign="top" align="center" rowspan="1" colspan="1">176 (32.4)</td><td valign="top" align="center" rowspan="1" colspan="1">174 (66.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ECPs</td><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">85 (66.4)</td><td valign="top" align="center" rowspan="1" colspan="1">177 (67.6)</td><td valign="top" align="center" rowspan="1" colspan="1">353 (32.9)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Status of prior ECPs use</td><td valign="top" align="center" rowspan="1" colspan="1">Correct</td><td valign="top" align="center" rowspan="1" colspan="1">77 (83.7)</td><td valign="top" align="center" rowspan="1" colspan="1">68 (78.2)</td><td valign="top" align="center" rowspan="1" colspan="1">145 (81)</td><td valign="top" align="center" rowspan="1" colspan="1">0.573</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Incorrect</td><td valign="top" align="center" rowspan="1" colspan="1">11 (12)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (17.2)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (4.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Do not remember</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (4.6)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (14.5)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>Time intervals between unprotected intercourse and the first and the second administration of ECPs in both treatment groups are given in <xref ref-type="table" rid="T3">Table 3</xref>. Majority of the participants (66.5% in HD group and 66% in LNG group) had used the tablets within 12 h of unguarded intercourse. No case of drug administration after 72 h was reported. Seven women in HD group versus one woman in LNG group had not taken the second dose (<italic>P</italic> = 0.059). Percentage of correct use of ECPs (including the act of intercourse within one week of drug administration) was significantly higher in HD group.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3:</label><caption><p>Status of drug administration among participants</p></caption><table frame="hsides" rules="all" cellspacing="5" cellpadding="5" border="1"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">Status</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) in HD group</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) in LNG group</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) total</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value <break/>(chi-square)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Time interval between coitus and drug administration</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c; 12 h</td><td valign="top" align="center" rowspan="1" colspan="1">177 (66.5)</td><td valign="top" align="center" rowspan="1" colspan="1">173 (66)</td><td valign="top" align="center" rowspan="1" colspan="1">350 (66.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.961</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">12-24 h</td><td valign="top" align="center" rowspan="1" colspan="1">31 (11.7)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (11.5)</td><td valign="top" align="center" rowspan="1" colspan="1">61 (11.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">24-48 h</td><td valign="top" align="center" rowspan="1" colspan="1">45 (16.9)</td><td valign="top" align="center" rowspan="1" colspan="1">48 (18.3)</td><td valign="top" align="center" rowspan="1" colspan="1">93 (17.6)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">48-72 h</td><td valign="top" align="center" rowspan="1" colspan="1">13 (4.9)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (4.2)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (4.5)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time interval between doses</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c; 12 h</td><td valign="top" align="center" rowspan="1" colspan="1">241 (90.6)</td><td valign="top" align="center" rowspan="1" colspan="1">237 (90.1)</td><td valign="top" align="center" rowspan="1" colspan="1">487 (90.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.059</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">12-24 h</td><td valign="top" align="center" rowspan="1" colspan="1">18 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (9.5)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (8.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Did not take</td><td valign="top" align="center" rowspan="1" colspan="1">7 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.4)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (1.5)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Status of ECP use</td><td valign="top" align="center" rowspan="1" colspan="1">Correct</td><td valign="top" align="center" rowspan="1" colspan="1">186 (69.9)</td><td valign="top" align="center" rowspan="1" colspan="1">161 (61.2)</td><td valign="top" align="center" rowspan="1" colspan="1">347 (65.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.035</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">Incorrect</td><td valign="top" align="center" rowspan="1" colspan="1">80 (30.1)</td><td valign="top" align="center" rowspan="1" colspan="1">102 (38.8)</td><td valign="top" align="center" rowspan="1" colspan="1">182 (34.4)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">week of drug administration</td><td valign="top" align="center" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">86 (32.6)</td><td valign="top" align="center" rowspan="1" colspan="1">123 (46.9)</td><td valign="top" align="center" rowspan="1" colspan="1">209 (39.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">No</td><td valign="top" align="center" rowspan="1" colspan="1">178 (67.4)</td><td valign="top" align="center" rowspan="1" colspan="1">139 (53.1)</td><td valign="top" align="center" rowspan="1" colspan="1">317 (60.3)</td><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>The rate of unwanted pregnancies due to unprotected intercourse was higher among participants in LNG group compared to HD group. Four women (1.5%) in LNG group had become pregnant, compared to three women (1.1%) in HD group, though the difference was not statistically significant (<italic>P</italic> = 0.723).</p><p>Frequency and severity (only in the case of nausea) of side effects of both LevonorgestrelandYuzpe regimens are given in <xref ref-type="table" rid="T4">Table 4</xref>. 75% of the participants in LNG group had not experienced nausea at all, and 19.8% had had mild nausea. In contrast, 62% of the participants in HD group had experienced mild and severe nausea, which is significantly higher than that of LNG group. In addition, frequency of vomiting and dizziness were also significantly higher in HD group. Fatigue and headache were more observed in HD group, though the difference was not significant. In the case of other side effects, no differences were observed.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4:</label><caption><p>Frequency of side effects within one week of drug administration</p></caption><table frame="hsides" rules="all" cellspacing="5" cellpadding="5" border="1"><thead><tr><th valign="top" align="center" rowspan="1" colspan="1">Side effects</th><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) in HD group</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) in LNG group</th><th valign="top" align="center" rowspan="1" colspan="1">Frequency (Percentage) total</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value <break/>(chi-square)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td><td valign="top" align="left" rowspan="1" colspan="1">Severe</td><td valign="top" align="center" rowspan="1" colspan="1">66 (24.8)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (4.6)</td><td valign="top" align="center" rowspan="1" colspan="1">78 (14.7)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="center" rowspan="1" colspan="1">99 (37.2)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (19.8)</td><td valign="top" align="center" rowspan="1" colspan="1">151 (28.5)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="center" rowspan="1" colspan="1">101 (38)</td><td valign="top" align="center" rowspan="1" colspan="1">199 (75.7)</td><td valign="top" align="center" rowspan="1" colspan="1">300 (56.7)</td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">73 (24.7)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (3.4)</td><td valign="top" align="center" rowspan="1" colspan="1">82 (15.5)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Headache</td><td valign="top" align="center" rowspan="1" colspan="1">122 (45.9)</td><td valign="top" align="center" rowspan="1" colspan="1">106 (40.3)</td><td valign="top" align="center" rowspan="1" colspan="1">228 (43.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.197</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Fatigue</td><td valign="top" align="center" rowspan="1" colspan="1">124 (46.6)</td><td valign="top" align="center" rowspan="1" colspan="1">102 (38.8)</td><td valign="top" align="center" rowspan="1" colspan="1">226 (42.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.069</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Dizziness</td><td valign="top" align="center" rowspan="1" colspan="1">125 (47)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (37.3)</td><td valign="top" align="center" rowspan="1" colspan="1">223 (42.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.023</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Breast tenderness</td><td valign="top" align="center" rowspan="1" colspan="1">51 (19.2)</td><td valign="top" align="center" rowspan="1" colspan="1">58 (22.1)</td><td valign="top" align="center" rowspan="1" colspan="1">109 (20.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.413</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Stomach pain</td><td valign="top" align="center" rowspan="1" colspan="1">106 (39.8)</td><td valign="top" align="center" rowspan="1" colspan="1">105 (39.9)</td><td valign="top" align="center" rowspan="1" colspan="1">211 (39.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.986</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Nose spot</td><td valign="top" align="center" rowspan="1" colspan="1">56 (21.1)</td><td valign="top" align="center" rowspan="1" colspan="1">61 (23.2)</td><td valign="top" align="center" rowspan="1" colspan="1">117 (22.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.553</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Diarrhea</td><td valign="top" align="center" rowspan="1" colspan="1">54 (20.3)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (19)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (19.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.709</td></tr></tbody></table></table-wrap><p>Finally, the amount of menstrual bleeding before and after drug administration is given in <xref ref-type="table" rid="T5">Table 5</xref>. The level of the change occurred in bleeding patterns of each group is also shown in this table. The menstrual bleeding after drug administration had occurred more heavily, compared to that before the drug administration. However, since the change had occurred in both groups, no statistically significant change observed in menstrual bleeding pattern due to drug administration between treatment groups.</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5:</label><caption><p>Amount of menstrual bleeding before and after drug administration and the resulting changes in menstrual bleeding patterns</p></caption><table frame="hsides" rules="all" cellspacing="5" cellpadding="5" border="1"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">Mean (SD) in HD group</th><th valign="top" align="center" rowspan="1" colspan="1">Mean (SD) in LNG group</th><th valign="top" align="center" rowspan="1" colspan="1">Mean (SD) total</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic> value <break/>(chi-square)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Spotting before drug administration</td><td valign="top" align="center" rowspan="1" colspan="1">38.8 (21.9)</td><td valign="top" align="center" rowspan="1" colspan="1">40.3 (21.8)</td><td valign="top" align="center" rowspan="1" colspan="1">39.5 (21.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.428</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Spotting after drug administration</td><td valign="top" align="center" rowspan="1" colspan="1">35.2 (22.8)</td><td valign="top" align="center" rowspan="1" colspan="1">38.7 (25.5)</td><td valign="top" align="center" rowspan="1" colspan="1">36.9 (24.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.093</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Change of spotting pattern</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;3.6 (22.1)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.5 (25.5)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;2.6 (23.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.326</td></tr></tbody></table></table-wrap></sec><sec><title>Discussion</title><p>According to the results from present study, complete knowledge of emergency contraception is quite low among women in Gilan province, Iran (only 8% in HD group and 8.6% in LNG group had sound complete knowledge about ECPs), which is consistent with results from other studies. Although quite critical, knowledge of ECPs is very low in developing countries such as Cameron (<xref rid="ref27" ref-type="bibr">27</xref>), Uganda (<xref rid="ref28" ref-type="bibr">28</xref>), Nigeria (<xref rid="ref29" ref-type="bibr">29</xref>), and South Africa (<xref rid="ref30" ref-type="bibr">30</xref>), even among health care providers (<xref rid="ref31" ref-type="bibr">31</xref>), compared to that in highly developed countries such as USA (<xref rid="ref32" ref-type="bibr">32</xref>). This is the most important reason for the low rate of ECP use in such countries and brings about the need for extensive education of ECPs for sexually active women. Extensive education combined with increased access to ECPs through pharmacies without prescription as an over-the-counter medicine can highly increase the rate of ECP use and reduce the medical costs posed to society due to unwanted pregnancies (<xref rid="ref5" ref-type="bibr">5</xref>&#x02013;<xref rid="ref7" ref-type="bibr">7</xref>), as experienced in USA and England (<xref rid="ref33" ref-type="bibr">33</xref>, <xref rid="ref34" ref-type="bibr">34</xref>).</p><p>We failed to distinguish a statistically significant difference in pregnancy rates between the treatment groups that was previously observed by other randomized controlled trials (<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref16" ref-type="bibr">16</xref>). The first reason can be assigned to the low number of sample size. According to Task Force on Postovulatory Methods of Fertility Regulation (<xref rid="ref15" ref-type="bibr">15</xref>), if a 2.1% difference had to be distinguished in our society, 744 participants would have needed in each group. In our study, however, 529 compiled with eligibility criteria were classified into two groups (266 women in HD group and 263 women in LNG group). This implies inadequate power of the present study to distinguish a significant difference in efficiencies of the treatment groups. The other reason can be assigned to greater number of intercourse within one week of drug administration in LNG group due to having lower side effects, which lowers the efficiency of the Levonorgestrel group.</p><p>Nonetheless, our study has some advantages over the previous studies conducted in Iran. The study of Farajkhoda et al. (<xref rid="ref25" ref-type="bibr">25</xref>) was conducted with a small sample size. This combined with the low rate of expected pregnancy led to a negligible statistical power in revealing the possible difference between the efficiency of the two methods (with only 62 and 60 individuals in intervention and control groups, respectively). In addition, they did not measure the serum level of Beta-HCG at the time of administering the pills. Therefore, they could not have left out the possibility of pregnancy from previous cycles. In other words, there was still the possibility that some of the participants had gotten pregnant from previous unprotected intercourses. In this situation, there is no indication for administration of the drug at this stage. This effect can undermine the validity of the findings with respect to the efficiency of the drug. In another study conducted by Broomandfar et al. (<xref rid="ref26" ref-type="bibr">26</xref>) in Iran, although the authors pointed out a significant difference between the efficiency of the two methods (100% vs. 94% with a <italic>P</italic>-value of 0.04), re-analysis of the data revealed that the difference was not statistically significant. Furthermore, their sample size was quite small, including only 68 women in both groups. In addition, like the first study, they did not measure the serum level of Beta-HCG before administrating contraceptive pills, which again could have led to miscalculation of the efficiency of the contraceptive methods.</p><p>In our study, however, we measured the serum levels of Beta-HCG both before and after the administration of the contraceptive pills. The participants were included only if the hormone level was negative before administration of the pills. In case the serum level of this hormone became positive after administration of each group of pills, they were considered as failure cases for that method.</p><p>Our sample size, however, was large enough for comparing side effects of the two regimens. For this purpose, 90 participants were needed in each group according to power calculations. Frequency and severity of side effects were, as it was expected, significantly higher among participants in HD group, especially in the case of nausea, vomiting, and dizziness, which is consistent with results of other studies. According to Task Force on Postovulatory Methods of Fertility Regulation (<xref rid="ref15" ref-type="bibr">15</xref>), side effects of Levonorgestrel were reported to be significantly lower than those of Yuzpe regimen. This was also supported by another multicenter, double-blind, randomized controlled trial study (<xref rid="ref16" ref-type="bibr">16</xref>). It is noteworthy that the considerably lower side effects of Levonorgestrel might be a reason for higher act of intercourse after drug administration in LNG group (due to better general status of women after drug administration in LNG group), resulting in higher pregnancy rate in this group and one reason for failure of the study to show the expected greater efficacy of Levonorgestrel regimen.</p><p>Finally, in contrast with our expectations, change of menstrual bleeding pattern was quite the same for both groups (<xref ref-type="table" rid="T5">Table 5</xref>), which is in agreement with the results presented by lee et al. (<xref rid="ref16" ref-type="bibr">16</xref>). Change occurs in spotting pattern due to administration of hormonal contraceptives is a challenging issue because its acceptability among women is highly culture- and religion-dependent (<xref rid="ref35" ref-type="bibr">35</xref>). In the past, for example, women used to prefer regular menstrual cycles, whereas having less spotting cycles is more acceptable in the developed world (<xref rid="ref36" ref-type="bibr">36</xref>). Or, less spotting cycles and even amenorrhea is more acceptable among white women compared to blacks (<xref rid="ref37" ref-type="bibr">37</xref>). Therefore, since Iran is considered a religious country and change of spotting pattern can interrupt religious activities of Iranian women, use of ECPs should be assessed with respect to implications on menstrual cycle. A considerable body of evidence now exists, which supports greater efficiency of and milder side effects of Levonorgestrel compared to that of Yuzpe regimen. In Iran, however, Yuzpe is still the only emergency contraception method available. Therefore, it is recommended that Levonorgestrel be also available in Iranian governmental family planning centers for free and its use be encouraged by improving the level of knowledge among sexually active women as well as increasing and facilitating their access to it.</p></sec><sec><title>Conclusion</title><p>Complete knowledge and use of emergency contraceptive pills is quite low in Iran and further education as well as increased accessibility of ECPs is critical. Although patterns of menstrual bleeding was the same in both treatment groups, significantly fewer side effects of Levonorgestrel compared to those of Yuzpe regimen leads to greater acceptability of the former and can also be translated to greater efficiency. Therefore, it is recommended that Levonorgestrel be also available in Iranian governmental family planning centers for free so that it can gradually replace Yuzpe regimen.</p></sec><sec><title>Ethical Considerations</title><p>Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc) have been completely observed by the authors.</p></sec></body><back><ack><title>Acknowledgement</title><p>The present study was funded partly by Deputy Ministry for Research Tehran University of Medical Sciences, grant #132/10442 and in part by Population Family and School Health Dept., Ministry of Health and Medical Education We would like to thank Family Planning Office, Gilan University of Medical Sciences and Vali-e-Asr Reproductive Health Research Center for their corporation in this work. We also thank Iran Hormone Company, for providing us with the Contraceptive Pills used in this study. The authors declare that there is no conflict of interest, except for the provision of contraceptive pills by Iran Hormone Company, which is also in charge of importing these pills. However, the authors declare that the statements made in the papers are those of authors and do not reflect the ideas of the funding body or those of the Iran Hormone Company.</p></ack><ref-list><title>References</title><ref id="ref1"><label>1</label><mixed-citation publication-type="book"><collab>Anonymous</collab> (<year>1998</year>). <article-title>Family care international, fact sheets</article-title>. <publisher-loc>New York</publisher-loc> Available from: <uri xlink:type="simple" xlink:href="www.safemo-therhood.org">www.safemo-therhood.org</uri></mixed-citation></ref><ref id="ref2"><label>2</label><mixed-citation publication-type="book"><string-name><surname>Bazazian</surname>
<given-names>S</given-names></string-name> (<year>2002</year>). <article-title>Evaluating unwanted pragnancies among Tehranian woman with positive pregnancy test</article-title>. [MS thesis]. <publisher-name>Department of Obstetrics, Tehran University of Medical Sciences</publisher-name>, <publisher-loc>Iran</publisher-loc>.</mixed-citation></ref><ref id="ref3"><label>3</label><mixed-citation publication-type="book"><collab>WHO</collab> (<year>1998</year>). <article-title>Emergency contraception, A guide for service delivery</article-title>. <publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva</publisher-loc> Available from: <uri xlink:type="simple" xlink:href="www.who.int">www.who.int</uri></mixed-citation></ref><ref id="ref4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Wai Ngai</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Jing</surname>
<given-names>X</given-names></string-name>
<etal/> (<year>2005</year>). <article-title>A randomized trial to compare 24&#x02009;h versus 12&#x02009;h double dose regimen of levonorgestrel for emergency contraception</article-title>. <source>Hum Reprod</source>, <volume>20</volume>: <fpage>307</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">15567882</pub-id></mixed-citation></ref><ref id="ref5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Marciante</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Gardner</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Veenstra</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Sullivan</surname>
<given-names>SD</given-names></string-name> (<year>2001</year>). <article-title>Modeling the cost and outcomes of pharmacist-prescribed emergency contraception</article-title>. <source>Am J Public Health</source>, <volume>91</volume>: <fpage>1443</fpage>&#x02013;<lpage>1445</lpage>.<pub-id pub-id-type="pmid">11527778</pub-id></mixed-citation></ref><ref id="ref6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Soon</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Meckley</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Levine</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Marciante</surname>
<given-names>KD</given-names></string-name>, <string-name><surname>Fielding</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Ensom</surname>
<given-names>MHH</given-names></string-name> (<year>2007</year>). <article-title>Modelling costs and outcomes of expanded availability of emergency contraceptive use in British Columbia</article-title>. <source>Canadian Journal of Clinical Pharmacology</source>, <volume>14</volume>: <fpage>326</fpage>&#x02013;<lpage>338</lpage>.</mixed-citation></ref><ref id="ref7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Trussell</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Koenig</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stewart</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Darroch</surname>
<given-names>JE</given-names></string-name> (<year>1997</year>). <article-title>Medical care cost savings from adolescent contraceptive use</article-title>. <source>Fam Plann Perspect</source>, <volume>29</volume>: <fpage>248</fpage>&#x02013;<lpage>255</lpage>.<pub-id pub-id-type="pmid">9429869</pub-id></mixed-citation></ref><ref id="ref8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Yuzpe</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Rademaker</surname>
<given-names>AW</given-names></string-name> (<year>1982</year>). <article-title>A multicenter clinical investigation employing ethinyl estradiol combined with dlnorgestrel as postcoital contraceptive agent</article-title>. <source>Fertil Steril</source>, <volume>37</volume>: <fpage>508</fpage>&#x02013;<lpage>513</lpage>.<pub-id pub-id-type="pmid">7040117</pub-id></mixed-citation></ref><ref id="ref9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Creinin</surname>
<given-names>MD</given-names></string-name> (<year>1997</year>). <article-title>A reassessment of efficacy of the Yuzpe regimen of emergency contraception</article-title>. <source>Hum Reprod</source>, <volume>12</volume>: <fpage>496</fpage>&#x02013;<lpage>498</lpage>.<pub-id pub-id-type="pmid">9130749</pub-id></mixed-citation></ref><ref id="ref10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Webb</surname>
<given-names>A</given-names></string-name> (<year>1999</year>). <article-title>Emergency contraception: is it time to change method?</article-title>
<source>BMJ</source>, <volume>318</volume>: <fpage>342</fpage>&#x02013;<lpage>343</lpage>.<pub-id pub-id-type="pmid">9933174</pub-id></mixed-citation></ref><ref id="ref11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Webb</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Russel</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Elstein</surname>
<given-names>M</given-names></string-name> (<year>1992</year>). <article-title>Comparison of Yuzpe regimen, danazol and mifepristone (RU486) in oral postcoital contraception</article-title>. <source>Brit Med J</source>, <volume>305</volume>: <fpage>927</fpage>&#x02013;<lpage>931</lpage>.<pub-id pub-id-type="pmid">1458074</pub-id></mixed-citation></ref><ref id="ref12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Xiao</surname>
<given-names>BL</given-names></string-name>, <string-name><surname>von Hertzen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Piaggio</surname>
<given-names>G</given-names></string-name> (<year>2002</year>). <article-title>A randomized double-blind comparison of two single doses of mifepristone for emergency contraception</article-title>. <source>Hum Reprud</source>, <volume>17</volume>: <fpage>3084</fpage>&#x02013;<lpage>3089</lpage>.</mixed-citation></ref><ref id="ref13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Ashok</surname>
<given-names>PW</given-names></string-name>, <string-name><surname>Hamoda</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Flett</surname>
<given-names>GMM</given-names></string-name>, <string-name><surname>Templeton</surname>
<given-names>A</given-names></string-name> (<year>2004</year>). <article-title>Mifepristone versus the Yuzpe regimen (PC4) for emergency contraception</article-title>. <source>Int J Gynecol Obsted</source>, <volume>87</volume>: <fpage>188</fpage>&#x02013;<lpage>193</lpage>.</mixed-citation></ref><ref id="ref14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Ho</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Kwan</surname>
<given-names>MS</given-names></string-name> (<year>1993</year>). <article-title>A prospective randomized comparison of Levonorgestrel with the Yuzpe regimen in postcoital contraception</article-title>. <source>Hum Reprod</source>, <volume>8</volume>: <fpage>389</fpage>&#x02013;<lpage>392</lpage>.<pub-id pub-id-type="pmid">8473453</pub-id></mixed-citation></ref><ref id="ref15"><label>15</label><mixed-citation publication-type="journal"><collab>Anonymous</collab> (<year>1998</year>). <article-title>Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception</article-title>. <source>The Lancet</source>, <volume>352</volume>: <fpage>428</fpage>&#x02013;<lpage>433</lpage>.</mixed-citation></ref><ref id="ref16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Dunn</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>MF</given-names></string-name> (<year>1999</year>). <article-title>Levonorgestrel versus the &#x02018;Yuzpe&#x0201d; regimen</article-title>. <source>Can Fam Physician</source>, <volume>45</volume>: <fpage>629</fpage>&#x02013;<lpage>631</lpage>.<pub-id pub-id-type="pmid">10099801</pub-id></mixed-citation></ref><ref id="ref17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Johansson</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Brache</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Alvarez</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Faundes</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cochon</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Ranta</surname>
<given-names>S</given-names></string-name>
<etal/> (<year>2002</year>). <article-title>Phar-macokinetic study of defferent design regimens of Levonorgestrel for emergency contraception in healthy women</article-title>. <source>Hum Reprod</source>, <volume>17</volume>: <fpage>1472</fpage>&#x02013;<lpage>1476</lpage>.<pub-id pub-id-type="pmid">12042264</pub-id></mixed-citation></ref><ref id="ref18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Dada</surname>
<given-names>OA</given-names></string-name>, <string-name><surname>Godfrey</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Piaggio</surname>
<given-names>G</given-names></string-name>, <string-name><surname>von Hertzen</surname>
<given-names>H</given-names></string-name> (<year>2010</year>). <article-title>A randomized, double-blind, noninferiority study to compare two regimens of Levonorgestrel for emergency contraception in Nigeria</article-title>. <source>Contraception</source>, <volume>82</volume>: <fpage>373</fpage>&#x02013;<lpage>378</lpage>.<pub-id pub-id-type="pmid">20851232</pub-id></mixed-citation></ref><ref id="ref19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>von Hertzen</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Piaggio</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Peregoudov</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>S</given-names></string-name>
<etal/> (<year>2002</year>). <article-title>Low dose mifepristone and two regimens of levono-rgestrel for emergency contraception: a WHO multicentre randomised trial</article-title>. <source>The Lancet</source>, <volume>360</volume>: <fpage>1803</fpage>&#x02013;<lpage>1810</lpage>.</mixed-citation></ref><ref id="ref20"><label>20</label><mixed-citation publication-type="journal"><string-name><surname>Weismiller</surname>
<given-names>DJ</given-names></string-name> (<year>2004</year>). <article-title>Emergency contraception</article-title>. <source>AAFP</source>, <volume>70</volume>: <fpage>797</fpage>&#x02013;<lpage>714</lpage>.</mixed-citation></ref><ref id="ref21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Ellertson</surname>
<given-names>C</given-names></string-name> (<year>1996</year>). <article-title>History and efficacy of emergency contraception: Beyond Coca-Cola</article-title>. <source>Fam Plann Perspect</source>, <volume>28</volume>: <fpage>44</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">8777937</pub-id></mixed-citation></ref><ref id="ref22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Benagiano</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Carrara</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Filippi</surname>
<given-names>V</given-names></string-name> (<year>2009</year>). <article-title>Safety, efficacy and patient satisfaction with continuous daily administration of Levonorgestrel /-ethinylestradiol oral contraceptives</article-title>. <source>Patient Prefer Adher</source>, <volume>3</volume>: <fpage>131</fpage>&#x02013;<lpage>143</lpage>.</mixed-citation></ref><ref id="ref23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Raymond</surname>
<given-names>EG</given-names></string-name>, <string-name><surname>Goldberg</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Trussell</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hays</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Roach</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Taylor</surname>
<given-names>D</given-names></string-name> (<year>2006</year>). <article-title>Bleeding patterns after use of Levonorgestrel emergency contrac-eptive pills</article-title>. <source>Contraception</source>, <volume>73</volume>: <fpage>376</fpage>&#x02013;<lpage>381</lpage>.<pub-id pub-id-type="pmid">16531171</pub-id></mixed-citation></ref><ref id="ref24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Tirelli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Cagnacci</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Volpe</surname>
<given-names>A</given-names></string-name> (<year>2008</year>). <article-title>Levo-norgestrel administration in emergency contraception: bleeding pattern and pituitary-ovarian function</article-title>. <source>Contraception</source>, <volume>77</volume>: <fpage>328</fpage>&#x02013;<lpage>332</lpage>.<pub-id pub-id-type="pmid">18402847</pub-id></mixed-citation></ref><ref id="ref25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Farajkhoda</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Khoshbin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Enjezab</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Bokaei</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Karimi Zarchi</surname>
<given-names>M</given-names></string-name> (<year>2009</year>). <article-title>Assessment of Two Emergency Contraceptive Regimens in Iran: Levonorgestrel Versus the Yuzpe</article-title>. <source>Niger J Clin Pract</source>, <volume>12</volume>: <fpage>450</fpage>&#x02013;<lpage>452</lpage>.<pub-id pub-id-type="pmid">20329690</pub-id></mixed-citation></ref><ref id="ref26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Broomandfar</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Godarzy</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Alameh</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Hoseiny</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Askary</surname>
<given-names>AH</given-names></string-name> (<year>2008</year>). <article-title>Comparison of efficiency and some complications of HD and Levonorgestrel tables as an emergency contraceptive method</article-title>. <source>Iranian J Nursing Midwifery Res</source>, <volume>13</volume>: <fpage>104</fpage>&#x02013;<lpage>109</lpage>.</mixed-citation></ref><ref id="ref27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Kongnyuy</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ngassa</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Fomulu</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Wiysonge</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kouam</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Doh</surname>
<given-names>A</given-names></string-name> (<year>2007</year>). <article-title>A survey of knowledge, attitudes and practice of emergency contraception among university students in Cameroon</article-title>. <source>BMC Emerg Med</source>, <volume>7</volume>: <fpage>7</fpage>.<pub-id pub-id-type="pmid">17634106</pub-id></mixed-citation></ref><ref id="ref28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Byamugisha</surname>
<given-names>JK</given-names></string-name>, <string-name><surname>Mirembe</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Faxelid</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Gemzell-Danielsson</surname>
<given-names>K</given-names></string-name> (<year>2006</year>). <article-title>Emergency contraception and fertility awareness among university students in Kampala, Uganda</article-title>. <source>Afr Health Sci</source>, <volume>6</volume>: <fpage>194</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">17604507</pub-id></mixed-citation></ref><ref id="ref29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Akani</surname>
<given-names>CI</given-names></string-name>, <string-name><surname>Enyindah</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Babatunde</surname>
<given-names>S</given-names></string-name> (<year>2008</year>). <article-title>Emergency contraception: Knowledge and perception of female undergraduates in the Niger delta of Nigeria</article-title>. <source>Ghana Med J</source>, <volume>42</volume>: <fpage>68</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">19180206</pub-id></mixed-citation></ref><ref id="ref30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Myer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Mlobeli</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cooper</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Smit</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Morroni</surname>
<given-names>C</given-names></string-name> (<year>2007</year>). <article-title>Knowledge and use of emergency contraception among women in the Western Cape province of South Africa: a cross-sectional study</article-title>. <source>BMC Women&#x02019;s Health</source>, <volume>7</volume>: <fpage>14</fpage>.<pub-id pub-id-type="pmid">17850659</pub-id></mixed-citation></ref><ref id="ref31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Yam</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Gordon-Strachan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>McIntyre</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Fletcher</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Garcia</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Becker</surname>
<given-names>D</given-names></string-name>
<etal/> (<year>2007</year>). <article-title>Jamaican and Barbadian health care providers&#x02019; knowledge, attitudes and practices regarding emergency contraceptive pills</article-title>. <source>Int Fam Plann Perspect</source>, <volume>33</volume>: <fpage>160</fpage>&#x02013;<lpage>167</lpage>.</mixed-citation></ref><ref id="ref32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Kang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Moneyham</surname>
<given-names>L</given-names></string-name> (<year>2008</year>). <article-title>Use of emergency contraceptive pills and condoms by college students: A survey</article-title>. <source>Int J Nurs Stud</source>, <volume>45</volume>: <fpage>775</fpage>&#x02013;<lpage>783</lpage>.<pub-id pub-id-type="pmid">17349645</pub-id></mixed-citation></ref><ref id="ref33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Killick</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Irving</surname>
<given-names>G</given-names></string-name> (<year>2004</year>). <article-title>A national study examining the effect of making emergency hormonal contraception available without prescription</article-title>. <source>Hum Reprod</source>, <volume>19</volume>: <fpage>553</fpage>&#x02013;<lpage>557</lpage>.<pub-id pub-id-type="pmid">14998950</pub-id></mixed-citation></ref><ref id="ref34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Raine</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Harper</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Rocca</surname>
<given-names>CH</given-names></string-name>, <string-name><surname>Fischer</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Padian</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Klausner</surname>
<given-names>JD</given-names></string-name>
<etal/> (<year>2005</year>). <article-title>Direct Access to Emergency Contraception Through Pharmacies and Effect on Unintended Pregnancy and STIs: A Randomized Controlled Trial</article-title>. <source>JAMA</source>, <volume>293</volume>: <fpage>54</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">15632336</pub-id></mixed-citation></ref><ref id="ref35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Snow</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Hardy</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Kneuper</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Hebling</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>G</given-names></string-name> (<year>2007</year>). <article-title>Women&#x02019;s responses to menses and nonbleeding intervals in the USA, Brazil and Germany</article-title>. <source>Contraception</source>, <volume>76</volume>: <fpage>23</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">17586132</pub-id></mixed-citation></ref><ref id="ref36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Glasier</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>van der Spuy</surname>
<given-names>ZM</given-names></string-name>, <string-name><surname>Ho</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Dada</surname>
<given-names>K</given-names></string-name>, <etal/>(<year>2003</year>). <article-title>Amenorrhea associated with contraception--an international study on acceptability</article-title>. <source>Contraception</source>, <volume>67</volume>: <fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">12521650</pub-id></mixed-citation></ref><ref id="ref37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Edelman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lew</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cwiak</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Nichols</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Jensen</surname>
<given-names>J</given-names></string-name> (<year>2007</year>). <article-title>Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women</article-title>. <source>Contraception</source>, <volume>75</volume>: <fpage>450</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">17519151</pub-id></mixed-citation></ref></ref-list></back></article>